ProQR Announces Third Quarter 2021 Operating and Financial Results Press release Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022 Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing pla November 04, 2021